Thur 8 May
0745 - 0845
1A Epilepsy | 1C Neuro Infection | 3A Peripheral Nerve | 3B TBI
Epilepsy
1A Chair: Lina Nashef
Paul Cooper: Predicting risk of epilepsy per year post head injury: When would DVLA requirements be met and when can driving resume? A neurologist’s guide
Tony Marson: Factors predicting recurrence after anti-seizure medication withdrawal and likelihood of regaining control in the event of recurrence
William Stern: An update on studies on valproate and possible transgenerational effect in men – how to safely navigate the uncertainty
Dorothy Jo: Surgery for epilepsy for low grade lesions in neuro-oncology practice – A missed opportunity?
Neuro Infection
1C Clinical Challenges in the Investigation and Management of Encephalitis
1C Chair: Benedict Michael
Benedict Michael: Welcome and Introduction
Lance Turtle: So you’ve been asked to see an encephalopathic, immunocompromised patient…
Laura Benjamin: So you’ve been asked to see an encephalopathic, returning traveller or migrant…
Michael Zandi: So you’ve been asked to see an encephalopathic patient with near normal CSF…
Mark Ellul: Q&A
Peripheral Nerve
3A Diabetic Neuropathies: Making it Painless
3A Chair: Tim Lavin
Matthew Evans: Small Fibre Neuropathies
Arjuna Nagendran: An approach to conduction slowing in a diabetic: Could it be CIDP?
TBI
3B The many faces of mild Traumatic Brain Injury
3B Chair: Peter Jenkins
Neil Graham: The long-term effects of sporting TBI: lessons from the Advanced Brain Health Clinic Study of retired rugby players
Damian Jenkins: TBI on the battlefield: mild TBI case study
Richard Sylvester: Legal controversies surrounding mild TBI
Lucia Li: Brief update on TBI REPORTER and relevance to ABN members
Fri 9 May
0750 - 0850
1A Cognitive | 1C Autonomic | 3A FND | 3B Neuro-oncology
Cognitive
1A Oncological interventions for Glioma – Time to involve the neurologist?
1A Chair: Akram Hosseini
Mike Zandi: Cognitive Dysfunction in AIE and antibody links (NMDAR, LGI-1)
Radu Tanasescu: Case Series & Audit Data
Chris Butler: Lessons for practising neurologists
Autonomic
1C Biomarkers of Early Autonomic Disease
1A Chair: Gordon Ingle
Gordon Ingle, Valeria Iodice, Patricia McNamara and Giacomo Chiaro present an overview of existing biomarkers and how these can be used in early assessment of autonomic failure. The session will involve interactive discussion, giving examples and case studies. The speakers will update on progress to make Droxidopa available for neurological use via NHS England and share plans for a UK wide Autonomic MDT and a UK Autonomic Society to work alongside the Special Interest Group.
FND
3A What should an FND service look like?
1A Chair: Marianne Novak
Marianne Novak, Beth Mallam & Christine Burness
The structure of FND services varies across existing UK services, while many regions do not have an FND service at all. There is significant inequality of access to specialist healthcare for people with FND as a result. We would like to (a) present three UK FND services as examples of different models, and (b) discuss what makes a successful FND service, what challenges are faced in developing and sustaining these services, and what are the ways in which we can support each other in developing new services.
Neuro-oncology
3B Oncological interventions for Glioma – Time to involve the neurologist?
1A Chair: Shanika Samarasekera
Catherine McBain: The potential benefits and side effects to date of Vorasidenib based on local experience
Sara Meade: Indigo and beyond: An overview of other Vorasidenib trials
Round table discussion: Should neurologists deliver oncological therapies – time for a reconfiguration of services?
Satheesh Ramalingam: Is it a tumour? Identifying radiologically- challenging lesions